Table 2.
The CIs at 90% effect level of the drug combinations
| Therapeutic drug | Inhibitor | Cell line | Cell line sensitivity to therapeutic drug | CI at 90% effect level | Effect |
|---|---|---|---|---|---|
| Cisplatin | Bortezomib | NCI-H23 | Sensitive | 1.30 | Moderate antagonism |
| U-2020 | Resistant | 0.61 | Synergism | ||
| b-AP15 | NCI-H23 | Sensitive | 0.41 | Synergism | |
| U-2020 | Resistant | 0.72 | Moderate synergism | ||
| Gefitinib | Bortezomib | U-2020 | Sensitive | ND | ND |
| NCI-H23 | Resistant | 0.37 | Synergism | ||
| b-AP15 | U-2020 | Sensitive | ND | ND | |
| NCI-H23 | Resistant | ND | ND | ||
| Gemcitabine | Bortezomib | NCI-H23 | Sensitive | 0.32 | Synergism |
| U-1752 | Resistant | 0.28 | Strong synergism | ||
| b-AP15 | NCI-H23 | Sensitive | ND | ND | |
| U-1752 | Resistant | 0.56 | Synergism | ||
| Vinorelbine | Bortezomib | NCI-H23 | Sensitive | 0.94 | Nearly additive |
| U-2020 | Resistant | 0.38 | Synergism | ||
| b-AP15 | NCI-H23 | Sensitive | 0.63 | Synergism | |
| U-2020 | Resistant | 0.55 | Synergism |
ND not determinable due to poor curve fit by the CalcuSyn software